AVEO Pharmaceuticals (Nasdaq: AVEO) announced the presentation of results from four preclinical studies of AV-380, the Company’s potent, humanized inhibitory ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE